公开(公告)号：EP4491745A1

公开(公告)日：2025-01-15

申请号：EP23767176.3

申请日：2023-03-08

Applicant: Korea Advanced Institute of Science and Technology

Inventor： CHO, Kwang Hyun ,  GONG, Jeong Ryeol ,  KIM, Ju Hee

IPC: C12Q1/6886 ,  C12N9/10

Abstract: The present invention relates to a composition comprising a SETMAR inhibitor for preventing or treating cancer. It has been identified that if SETMAR is inhibited in cancer cells, carcinogenesis reversion, which is the differentiation of cancer cells into normal cells, is successfully achieved, and thus, unlike conventional anticancer agents that simply induce cancer cell death, the present invention can be effectively used as a treatment method excluding the side effect of normal cell death that can occur during anticancer treatment, and converting cancer cells into normal cells.

公开(公告)号：EP4497836A1

公开(公告)日：2025-01-29

申请号：EP23775342.1

申请日：2023-03-23

Applicant: Korea Advanced Institute of Science and Technology

Inventor： CHO, Kwang Hyun ,  GONG, Jeong Ryeol ,  LEE, Chun Kyung ,  KIM, Hoon Min ,  KIM, Ju Hee

IPC: C12Q1/6886 ,  C12N5/09 ,  C12N15/85 ,  A61P35/00

Abstract: The present invention relates to a method for constructing a gene network through a single-cell transcriptome and a method for discovering key genes in differentiation using same, and a composition for the prevention, alleviation, or treatment of colon cancer using the target discovered through the method. The method for constructing a gene network of key genes according to the present invention employs single-cell transcriptome data and thus can be applied to all single-cell transcriptome data. The combination of MYB/HDAC2/FOXA2 discovered upon application to colon cells can serve as a cancer treatment target that promotes the differentiation of colon cancer cells to revert same into differentiated normal cells.